JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Danaher Corp

Затворен

СекторЗдравеопазване

174.62 0.32

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

173.22

Максимум

176.42

Ключови измерители

By Trading Economics

Приходи

-168M

1B

Продажби

-887M

6B

P/E

Средно за сектора

34.936

67.147

EPS

2.06

Дивидентна доходност

0.77

Марж на печалбата

17.291

Служители

58,000

EBITDA

-514M

1.5B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+34.3% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.77%

2.36%

Следващи печалби

21.07.2026 г.

Следваща дата на дивидент

24.07.2026 г.

Следваща дата на екс-дивидент

26.06.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-11B

128B

Предишно отваряне

174.3

Предишно затваряне

174.62

Настроения в новините

By Acuity

23%

77%

76 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Danaher Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.04.2026 г., 11:36 ч. UTC

Печалби

Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains -- Update

21.04.2026 г., 11:00 ч. UTC

Печалби

Danaher Raises Adjusted Earnings Guidance, 1Q Revenue, Profit Rise

21.04.2026 г., 10:06 ч. UTC

Печалби

Danaher 1Q Adjsuted Core Revenue Rose 0.5% >DHR

21.04.2026 г., 10:05 ч. UTC

Печалби

Danaher Sees 2Q Adjsuted Core Revenue Up Low-Single Digits >DHR

21.04.2026 г., 10:05 ч. UTC

Печалби

Danaher Still Sees 2026 Adjsuted Core Revenue Up 3%-6% >DHR

21.04.2026 г., 10:05 ч. UTC

Печалби

Danaher Had Seen 2026 Adjusted EPS $8.35-$8.50 >DHR

21.04.2026 г., 10:04 ч. UTC

Печалби

Danaher Raises 2026 View To Adj EPS $8.35-Adj EPS $8.55 >DHR

21.04.2026 г., 10:04 ч. UTC

Печалби

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

21.04.2026 г., 10:00 ч. UTC

Печалби

Danaher 1Q Cont Ops EPS $1.45 >DHR

21.04.2026 г., 10:00 ч. UTC

Печалби

Danaher 1Q Adj EPS $2.06 >DHR

21.04.2026 г., 10:00 ч. UTC

Печалби

Danaher 1Q Sales $5.95B >DHR

21.04.2026 г., 10:00 ч. UTC

Печалби

Danaher 1Q EPS $1.45 >DHR

21.04.2026 г., 10:00 ч. UTC

Печалби

Danaher 1Q Net $1.03B >DHR

17.04.2026 г., 19:15 ч. UTC

Пазарно говорене

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17.04.2026 г., 19:07 ч. UTC

Пазарно говорене

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17.02.2026 г., 20:06 ч. UTC

Придобивния, сливания и поглъщания

This Medical-Devices Stock Is Soaring. Danaher Is Buying the Company. -- Barrons.com

17.02.2026 г., 15:14 ч. UTC

Придобивния, сливания и поглъщания

Masimo Stock on Pace for Record Gains After Danaher Strikes Deal -- WSJ

17.02.2026 г., 14:39 ч. UTC

Придобивния, сливания и поглъщания

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17.02.2026 г., 13:30 ч. UTC

Придобивния, сливания и поглъщания

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17.02.2026 г., 13:15 ч. UTC

Придобивния, сливания и поглъщания

Danaher Strikes $10 Billion Deal for Masimo -- Update

17.02.2026 г., 13:03 ч. UTC

Придобивния, сливания и поглъщания

Danaher To Fund Masimo Acquisition With Cash on Hand, Debt Financing >DHR

17.02.2026 г., 13:03 ч. UTC

Придобивния, сливания и поглъщания

Danaher Sees More Than $125M Annual Cost Synergies, More Than $50M Annual Revenue Synergies by Fifth Full Year >DHR MASI

17.02.2026 г., 13:02 ч. UTC

Придобивния, сливания и поглъщания

Danaher Sees Masimo Deal Adding About 70c to Adjusted EPS in Fifth Full Year >DHR MASI

17.02.2026 г., 13:02 ч. UTC

Придобивния, сливания и поглъщания

Danaher Sees Masimo Deal Adding 15c-20c to Adjusted EPS in First Full Year >DHR MASI

17.02.2026 г., 13:02 ч. UTC

Придобивния, сливания и поглъщания

Masimo To Be Acquired By Danaher For $180.00 Per Share >MASI DHR

17.02.2026 г., 13:01 ч. UTC

Придобивния, сливания и поглъщания

Danaher to Buy Masimo for Total Enterprise Value of About $9.9 Billion >DHR MASI

17.02.2026 г., 13:00 ч. UTC

Придобивния, сливания и поглъщания

Danaher to Buy Masimo for $180/Share >DHR MASI

17.02.2026 г., 13:00 ч. UTC

Придобивния, сливания и поглъщания

Danaher To Acquire Masimo Corporation >DHR MASI

17.02.2026 г., 11:09 ч. UTC

Придобивния, сливания и поглъщания

Danaher Strikes $10 Billion Deal for Masimo -- WSJ

17.02.2026 г., 11:09 ч. UTC

Придобивния, сливания и поглъщания

Danaher Acquisition of Masimo Set to Be Announced Tuesday, Sources Say -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Danaher Corp Прогноза

Ценова цел

By TipRanks

34.3% нагоре

12-месечна прогноза

Среден 233.74 USD  34.3%

Висок 270 USD

Нисък 184.04 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за Danaher Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

16 ratings

14

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

189.8851 / 196.5Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

76 / 347 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat